clinvestКачественная клиническая практикаKachestvennaya Klinicheskaya Praktika = Good Clinical Practice2588-05192618-8473ООО «Издательство ОКИ10.24411/2588-0519-2019-10077clinvest-456Research ArticleНОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВАNEW DRUGS AND HEALTH TECHNOLOGIESИнновационные лекарственные препараты для терапии первичных головных болей: мигреньInnovative drugs for the treatment of primary headaches: migrainehttps://orcid.org/0000-0003-3107-7636РешетькоО. В.ReshetkoO. V.

Решетько Ольга Вилоровна Автор – доктор медицинских наук профессор, заведующий кафедрой фармакологии

SPIN-код: 7569-7915

Reshetko Olga - MD, professor, Head of Department of Pharmacology

SPIN-code: 7569-7915

reshetko@yandex.ruГришинА. И.GrishinA. I.

Гришин Антон Игоревич - аспирант кафедры фармакологии

Grishin Anton - Post-graduate student, Department of Pharmacology

ФГБОУ ВО «Саратовский государственный медицинский университет им. В.И. Разумовского» Минздрава РоссииРоссияSaratov State Medical University named after VI. Razumovskiy of the Health Ministry of the Russian FederationRussian Federation2019221020190295104Copyright © Решетько О.В., Гришин А.И., 20192019Решетько О.В., Гришин А.И.Reshetko O.V., Grishin A.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.clinvest.ru/jour/article/view/456

The article presents information about innovative drugs for the treatment of primary headaches (in particular, migraine), which are at the stages of clinical or preclinical studies, or were recently introduced to the foreign pharmaceutical market. The classes of these drugs, their mechanism of action, as well as the results of past studies are presents in article.

мигреньпротивомигренозные лекарственные препаратыпервичные головные боликальцито-нин-ген-связанный пептидбольPACAP35-HT1Fmigraineantimigraine drugsprimary headachescalcitonin-gene-related peptide (GCRP)painPACAP35-HT1Referenceswho.int [интернет]. Всемирная Организация Здравоохранения. Информационный бюллетень Всемирной Организации Здравоохранения “Головные боли”, 2016 [доступ от 7.05.2019]. Доступ по ссылке https://www.who.int/ru/news-room/fact-sheets/detail/headache-disorderswho. int [internet]. Vsemirnaya Organizaciya Zdravoohraneniya. Informacionnyj byulleten Vsemirnoj Organizacii Zdravoohraneniya “Golovnye boli”, 2016 [dostup ot 7.05.2019]. Dostup po ssylke https://www.who.int/ru/news-room/fact-sheets/detail/headache-disorders (In Russ).Сидоренко И. Новые подходы к лечению головной боли напряжения // ReUpoNews. — 2013. — Т.2. — №6 — С. 66—68.Sidorenko I. Novye podkhody k lecheniyu golovnoi boli napryazheniya. NeiroNews. 2013;4(2):66-68. (In Russ).International Headache Society 2018. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. 2018;38(1):1-211. DOI: 10.1177/0333102417738202International Headache Society 2018. Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. 2018;38(1):1-211. DOI: 10.1177/0333102417738202Осипова В.В. Первичные головные боли: клиника, диагностика, терапия. Информационное письмо (для неврологов, терапевтов, врачей общей практики). — Ростов-на-Дону.: Издательство Антей. — 2011. — 51 с.Osipova VV. Pervichnye golovnye boli: klinika, diagnostika, terapiya. Informatsionnoe pis’mo (dlya nevrologov, terapevtov, vrachei obshchei praktiki). Rostov-na-Donu.: Izdatel’stvo Antei. 2011. (In Russ).Осипова В.В. Первичные головные боли: диагностика и лечение. Методические рекомендации. URL: https://clck.ru/JcagxOsipova VV. Pervichnye golovnye boli: diagnostika i lechenie. Metodicheskie rekomendatsii. (In Russ). URL: https://clck.ru/JcagxКое-что еще о мигрени // Наука и жизнь. — 2001. — №12.Koe-chto eshche o migreni. Nauka i zhizn. 2001;12. (In Russ).Садоха К.А., Головко Т.Г. Роль серотонина в патогенезе и лечении мигрени. Медицинские новости. — 2005. — №4. — С. 40-43.Sadokha KA, Golovko TG. Rol’ serotonina v patogeneze i lechenii migreni. Meditsinskie novosti. 2005;(4):40-43. (In Russ).Agosti RM. 5-HT1F- and 5-HT7-receptor agonists for the treatment of migraines. NS & Neurological Disorders — Drug Targets. 2007;6(4):235-237.Agosti RM. 5-HT1F- and 5-HT7-receptor agonists for the treatment of migraines. NS & Neurological Disorders — Drug Targets. 2007;6(4):235-237.Phebus LA, Ramadan NM, Skljarevski V, et al. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia. 2003;23(8):776-785.Phebus LA, Ramadan NM, Skljarevski V, et al. 5-HT1F receptor agonists in acute migraine treatment: a hypothesis. Cephalalgia. 2003;23(8):776-785.Азимова Ю.Э., Рачин А.П., Ищенко К.А., и др. Инновационные методы лечения мигрени // Российский медицинский журнал. — 2015. — Т. 23. — №30. — С. 27-30.Azimova YuE, Rachin AP, Ishchenko KA, et al. Innovatsionnye metody lecheniya migreni. Rossiiskii meditsinskii zhurnal. 2015;23(30):27-30. (In Russ).Дубенко О.Е. Кальцитонин-ген-связанный пептидпри мигрени: патогенетический фактор и терапевтическая мишень (обзор) // Международный неврологический журнал. — 2018. — Т.96. — №2. — С.38-44. DOI: 10.22141/2224-0713.2.96.2018.130481Dubenko OYe. Calcitonin gene-related peptide in migraine:the pathogenetic factor and therapeutic target (review). Mezhdunarodnyi nevrologicheskii zhurnal. 2018;(2):38-44. (In Russ). DOI: 10.22141/2224-0713.2.96.2018.130481Gomez-Mancilla B, Cutler NR, Leibowitz MT. Safety and Efficacy of PNU-142633, a Selective 5-HT1D Agonist, in Patients with Acute Migraine. Cefalgia. 2001;21(7):727-732. DOI: 10.1111/j.1468-2982.2001.00208.xGomez-Mancilla B, Cutler NR, Leibowitz MT. Safety and Efficacy of PNU-142633, a Selective 5-HT1D Agonist, in Patients with Acute Migraine. Cefalgia. 2001;21(7):727-732. DOI: 10.1111/j.1468-2982.2001.00208.xBrenchat A, et al. Role of peripheral versus spinal 5-HT(7) receptors in the modulation of pain undersensitizing conditions. European Journal of pain. 2012;16(1):72-81. DOI: 10.1016/j.ejpain.2011.07.004Brenchat A, et al. Role of peripheral versus spinal 5-HT(7) receptors in the modulation of pain undersensitizing conditions. European Journal of pain. 2012;16(1):72-81. DOI: 10.1016/j.ejpain.2011.07.004Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358(9289): 1230-1234. DOI: 10.1016/s0140-6736(01)06347-4Goldstein DJ, Roon KI, Offen WW, et al. Selective serotonin 1F (5-HT(1F)) receptor agonist LY334370 for acute migraine: a randomised controlled trial. Lancet. 2001;358(9289): 1230-1234. DOI: 10.1016/s0140-6736(01)06347-4clinicaltrials.gov [Internet]. A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT00384774clinicaltrials.gov [Internet]. A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT00384774clinicaltrials.gov [Internet]. Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT00883051clinicaltrials.gov [Internet]. Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT00883051Ferrari MD, Frkkil M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan — a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170-1178. DOI: 10.1177/0333102410375512Ferrari MD, Frkkil M, Reuter U, et al. Acute treatment of migraine with the selective 5-HT1F receptor agonist lasmiditan — a randomised proof-of-concept trial. Cephalalgia. 2010;30(10):1170-1178. DOI: 10.1177/0333102410375512Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, doseranging study. Lancet Neurology. 2012;11(5):405-413. DOI: 10.1016/S1474-4422(12)70047-9Farkkila M, Diener HC, Geraud G, et al. Efficacy and tolerability of lasmiditan, an oral 5-HT(1F) receptor agonist, for the acute treatment of migraine: a phase 2 randomised, placebo-controlled, parallel-group, doseranging study. Lancet Neurology. 2012;11(5):405-413. DOI: 10.1016/S1474-4422(12)70047-9clinicaltrials.gov [Internet]. Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine (SPARTAN) [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT02605174clinicaltrials.gov [Internet]. Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine (SPARTAN) [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT02605174clinicaltrials.gov [Internet]. An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine (GLADIATOR) [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT02565186clinicaltrials.gov [Internet]. An Open-label, Long-term, Safety Study of Lasmiditan for the Acute Treatment of Migraine (GLADIATOR) [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT02565186FierceBiotech [Internet]. Eli Lilly files for FDA approval of migraine drug lasmiditan [cited 2019 May 7]. Available from https://www.fiercebiotech.com/biotech/lilly-files-for-fda-approval-migraine-drug-lasmiditanFierceBiotech [Internet]. Eli Lilly files for FDA approval of migraine drug lasmiditan [cited 2019 May 7]. Available from https://www.fiercebiotech.com/biotech/lilly-files-for-fda-approval-migraine-drug-lasmiditanHealth Central [Internet]. New GCRP Migraine Treatments in Development — March, 2016, Report [cited 2019 May 7]. Available from https://www.healthcentral.com/article/new-gcrp-migraine-treatments-in-development-march-2016-reportHealth Central [Internet]. New GCRP Migraine Treatments in Development — March, 2016, Report [cited 2019 May 7]. Available from https://www.healthcentral.com/article/new-gcrp-migraine-treatments-in-development-march-2016-reportGang Yao, Tingmin Yu, Ximei Han, et al. Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis. Neural Regen Res. 2013;8(10):938-947. DOI: 10.3969/j.issn.1673-5374.2013.10.009Gang Yao, Tingmin Yu, Ximei Han, et al. Therapeutic effects and safety of olcegepant and telcagepant for migraine: A meta-analysis. Neural Regen Res. 2013;8(10):938-947. DOI: 10.3969/j.issn.1673-5374.2013.10.009Ho TW, Mannix LK, Assaid C, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304-1312. DOI: 10.1212/01.WNL.0000286940.29755.61Ho TW, Mannix LK, Assaid C, et al. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology. 2008;70(16):1304-1312. DOI: 10.1212/01.WNL.0000286940.29755.61clinicaltrials.gov [Internet]. MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT00797667clinicaltrials.gov [Internet]. MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) [cited 2019 May 7]. Available from https://www.clinicaltrials.gov/ct2/show/NCT00797667clinicaltrials.gov [Internet]. Trial in Adult Subjects With Acute Migraines [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03461757clinicaltrials.gov [Internet]. Trial in Adult Subjects With Acute Migraines [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03461757MPR [Internet]. Rimegepant Zydis ODT Beneficial in Phase 3 Migraine Trial [cited 2019 May 7]. Available from https://www.empr.com/home/news/drugs-in-the-pipeline/rimegepant-zydis-odt-beneficial-in-phase-3-migraine-trial/MPR [Internet]. Rimegepant Zydis ODT Beneficial in Phase 3 Migraine Trial [cited 2019 May 7]. Available from https://www.empr.com/home/news/drugs-in-the-pipeline/rimegepant-zydis-odt-beneficial-in-phase-3-migraine-trial/clinicaltrials.gov [Internet]. Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03732638clinicaltrials.gov [Internet]. Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03732638Drugs.com [Internet]. Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant [cited 2019 May 7]. Available from https://www.drugs.com/clinical_trials/biohaven-announces-completion-pre-nda-meeting-fda-oral-cgrp-receptor-antagonist-rimegepant-18098.htmlDrugs.com [Internet]. Biohaven Announces Completion of Pre-NDA Meeting With FDA for Oral CGRP Receptor Antagonist Rimegepant [cited 2019 May 7]. Available from https://www.drugs.com/clinical_trials/biohaven-announces-completion-pre-nda-meeting-fda-oral-cgrp-receptor-antagonist-rimegepant-18098.htmlAllergan [Internet]. Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine [cited 2019 May 7]. Available from https://www.allergan.com/news/news/thomson-reuters/allergan-announces-fda-acceptance-of-new-drug-applAllergan [Internet]. Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine [cited 2019 May 7]. Available from https://www.allergan.com/news/news/thomson-reuters/allergan-announces-fda-acceptance-of-new-drug-applclinicaltrials.gov [Internet]. Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE II) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02867709clinicaltrials.gov [Internet]. Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE II) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02867709clinicaltrials.gov [Internet]. Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE I) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02828020clinicaltrials.gov [Internet]. Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE I) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02828020clinicaltrials.gov [Internet]. An Extension Study to Evaluate the LongTerm Safety and Tolerability of Ubrogepant in the Treatment of Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02873221clinicaltrials.gov [Internet]. An Extension Study to Evaluate the LongTerm Safety and Tolerability of Ubrogepant in the Treatment of Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02873221Xu C, Shi L, Rao S, et al. EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP. The Journal of Headache and Pain. 2014 Sep;54(Suppl. 1):1417-1418. DOI: 10.1186/1129-2377-15-S1-G43Xu C, Shi L, Rao S, et al. EHMTI-0315. AMG 334, the first potent and selective human monoclonal antibody antagonist against the CGRP. The Journal of Headache and Pain. 2014 Sep;54(Suppl. 1):1417-1418. DOI: 10.1186/1129-2377-15-S1-G43Pharma World Magazine [Internet]. Erenumab to prevent migraine: results from phase III STRIBE [cited 2019 May 7]. Available from http://www.pharmaworldmagazine.com/erenumab-prevent-migraine-results-phase-iii-stribe/Pharma World Magazine [Internet]. Erenumab to prevent migraine: results from phase III STRIBE [cited 2019 May 7]. Available from http://www.pharmaworldmagazine.com/erenumab-prevent-migraine-results-phase-iii-stribe/Novartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting [Internet]. [cited 2019 May 7] Available from: https://www.novartis.com/news/media-releases/novartis-presents-data-demonstrating-efficacy-amg-334-erenumab-migraineNovartis presents data demonstrating efficacy of AMG 334 (erenumab) in migraine prevention at the American Headache Society Annual Meeting [Internet]. [cited 2019 May 7] Available from: https://www.novartis.com/news/media-releases/novartis-presents-data-demonstrating-efficacy-amg-334-erenumab-migrainefda.gov [Internet]. FDA approves novel preventive treatment for migraine [cited 2019 May 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-preventive-treatment-migrainefda.gov [Internet]. FDA approves novel preventive treatment for migraine [cited 2019 May 7]. Available from: https://www.fda.gov/news-events/press-announcements/fda-approves-novel-preventive-treatment-migraineTheGuardian.com [Internet]. First drug to prevent chronic migraines approved by EU [cited 2019 May 7]. Available from: https://www.theguardian.com/science/2018/jul/31/first-ever-pill-to-prevent-chronic-migraines-approved-by-euTheGuardian.com [Internet]. First drug to prevent chronic migraines approved by EU [cited 2019 May 7]. Available from: https://www.theguardian.com/science/2018/jul/31/first-ever-pill-to-prevent-chronic-migraines-approved-by-euNovartis [Internet]. Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine [cite 2019 May 7]. Available from https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovigr-erenumab-prevention-migraineNovartis [Internet]. Novartis receives positive CHMP opinion for Aimovig® (erenumab) for the prevention of migraine [cite 2019 May 7]. Available from https://www.novartis.com/news/media-releases/novartis-receives-positive-chmp-opinion-aimovigr-erenumab-prevention-migraineDrugs.com [Internet]. Aimovig Approval History [cited 2019 May 7]. Available from https://www.drugs.com/history/aimovig.htmlDrugs.com [Internet]. Aimovig Approval History [cited 2019 May 7]. Available from https://www.drugs.com/history/aimovig.htmlbiospace.com [Internet]. Pfizer Inc. To Acquire Rinat Neuroscience Corporation [cited 2019 May 7]. Available from https://www.biospace.com/article/releases/pfizer-inc-to-acquire-rinat-neuroscience-corporation-/biospace.com [Internet]. Pfizer Inc. To Acquire Rinat Neuroscience Corporation [cited 2019 May 7]. Available from https://www.biospace.com/ article/releases/pfizer-inc-to-acquire-rinat-neuroscience-corporation-/Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. Journal of the American Medical Association. 2018 May;319(19):1999-2008. DOI: 10.1001/jama.2018.4853Dodick DW, Silberstein SD, Bigal ME, et al. Effect of Fremanezumab Compared With Placebo for Prevention of Episodic Migraine: A Randomized Clinical Trial. Journal of the American Medical Association. 2018 May;319(19):1999-2008. DOI: 10.1001/jama.2018.4853Silberstein SD, McAllister P, Ning X, et al. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinicaltrials.gov. Headache: The journal of Head and Face Pain. 2019;59(6):880-890. DOI:10.1111/head.13534Silberstein SD, McAllister P, Ning X, et al. Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinicaltrials.gov. Headache: The journal of Head and Face Pain. 2019;59(6):880-890. DOI:10.1111/head.13534Medscape [Internet]. FDA Approves Fremanezumab (Ajovy) for Migraine Prevention [cited 2019 May 7]. Available from https://www.medscape.com/viewarticle/902071Medscape [Internet]. FDA Approves Fremanezumab (Ajovy) for Migraine Prevention [cited 2019 May 7]. Available from https://www.medscape.com/viewarticle/902071PMLive.com [Internet]. Teva’s migraine injection approved in Europe [cited 2019 May 7]. Available from https://www.pmlive.com/pharma_news/tevas_migraine_injection_approved_in_europe_1283616PMLive.com [Internet]. Teva’s migraine injection approved in Europe [cited 2019 May 7]. Available from https://www.pmlive.com/pharma_news/tevas_migraine_injection_approved_in_europe_1283616businesswire.com [Internet] Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults [cited 2019 May 7]. Available from https://www.businesswire.com/news/home/20190401005452/en/businesswire.com [Internet] Teva’s AJOVY® Receives EU Approval Offering Patients the First and Only Anti-CGRP Treatment with Both Quarterly and Monthly Dosing for the Prophylaxis of Migraine in Adults [cited 2019 May 7]. Available from https://www.businesswire.com/news/home/20190401005452/en/Drugs.com [Internet]. Fremanezumab [cited 2019 May 7]. Available from https://www.drugs.com/mtm/fremanezumab.htmlDrugs.com [Internet]. Fremanezumab [cited 2019 May 7]. Available from https://www.drugs.com/mtm/fremanezumab.htmlclinicaltrials.gov [Internet]. Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study (EVOLVE-1) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02614183clinicaltrials.gov [Internet]. Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study (EVOLVE-1) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02614183clinicaltrials.gov [Internet]. Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study (EVOLVE-2) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02614196clinicaltrials.gov [Internet]. Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study (EVOLVE-2) [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02614196clinicaltrials.gov [Internet] Evaluation of Galcanezumab in the Prevention of Chronic Migraine (REGAIN). [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02614261clinicaltrials.gov [Internet] Evaluation of Galcanezumab in the Prevention of Chronic Migraine (REGAIN). [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT02614261CNBC [Internet]. US FDA approves Lilly migraine drug at a price that is the same as its rivals [cited 019 May 7]. Available from https://www.cnbc.com/2018/09/28/us-fda-approves-lilly-migraine-drug-at-a-price-that-is-the-same-as-its-rivals.htmlCNBC [Internet]. US FDA approves Lilly migraine drug at a price that is the same as its rivals [cited 019 May 7]. Available from https://www.cnbc.com/2018/09/28/us-fda-approves-lilly-migraine-drug-at-a-price-that-is-the-same-as-its-rivals.htmlФармацевтический вестник [интернет]. Еврокомиссия одобрила Emgality для профилактики мигрени [доступ от 7.05.2019]. Доступно по ссылке https://pharmvestnik.ru/content/news/Evrokomissiya-odobrila-Emgality-dlya-profilaktiki-migreni.htmlФармацевтический вестник [интернет]. Еврокомиссия одобрила Emgality для профилактики мигрени [доступ от 7.05.2019]. Доступно по ссылке https://pharmvestnik.ru/content/news/Evrokomissiya-odobrila-Emgality-dlya-profilaktiki-migreni.htmlDrugs.com [Internet]. Galcanezumab [cited 2019 May 7]. Available from https://www.drugs.com/mtm/galcanezumab.htmlDrugs.com [Internet]. Galcanezumab [cited 2019 May 7]. Available from https://www.drugs.com/mtm/galcanezumab.htmlgrls.rosminzdrav.ru [интернет]. Государственный реестр лекарственных средств. Оценка эффективности и безопасности галканезумаба у пациентов с эпизодической мигренью [доступ от 7.05.2019]. Доступ по ссылке http://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=f2bb0510-0db1-4661-ba61-f26f0a1e42f0&CIPermGUID=B76D68CF-AB7B-4FD9-95E8-7A9B4F453F7Bgrls.rosminzdrav.ru [интернет]. Государственный реестр лекарственных средств. Оценка эффективности и безопасности галканезумаба у пациентов с эпизодической мигренью [доступ от 7.05.2019]. Доступ по ссылке http://grls.rosminzdrav.ru/CIPermissionMini.aspx?CIStatementGUID=f2bb0510-0db1-4661-ba61-f26f0a1e42f0&CIPermGUID=B76D68CF-AB7B-4FD9-95E8-7A9B4F453F7BAlder BioPharmaceuticals, Inc [Internet]. Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention [cited 2019 May 7]. Available from https://investor.alderbio.com/news-releases/news-release-details/alder-announces-eptinezumab-significantly-reduces-migraine-riskAlder BioPharmaceuticals, Inc [Internet]. Alder Announces Eptinezumab Significantly Reduces Migraine Risk Meets Primary and All Key Secondary Endpoints in Pivotal PROMISE 2 Phase 3 Trial for Chronic Migraine Prevention [cited 2019 May 7]. Available from https://investor.alderbio.com/news-releases/news-release-details/alder-announces-eptinezumab-significantly-reduces-migraine-riskРоссийская Фармацевтика [интернет]. FDA одобрило препарат для лечения эпизодической кластерной головной боли [доступ от 5.06.2019] . Доступ по ссылке http://pharmapractice.ru/156333Rossijskaya Farmacevtika [internet]. FDA odobrilo preparat dlya lecheniya epizodicheskoj klasternoj golovnoj boli [dostup ot 5.06.2019]. Dostup po ssylke http://pharmapractice.ru/156333 (In Russ).ГК Ремедиум [интернет]. Alder успешно испытала новый препарат для лечения мигрени [доступ от 7.05.2019]. Доступ по ссылке http://remedium.ru/news/detail.php?ID=73186 7.05.2019] . Dostup po ssylke http://remedium.ru/news/detail.php?ID=73186 (In Russ).]GK Remedium [internet]. Alder uspeshno ispytala novyj preparat dlya lecheniya migreni [dostup ot 7.05.2019] . Dostup po ssylke http://remedium.ru/news/detail.php?ID=73186 (In Russ).Alder BioPharmaceuticals, Inc [Internet]. Eptinezumab [cited 2019 may 2017]. Available from https://investor.alderbio.com/news-releases/ news-release-details/alder-announces-eptinezumab-significantly-reduces-migraine-riskhttps://www.alderbio.com/pipeline/eptinezumab/Alder BioPharmaceuticals, Inc [Internet]. Eptinezumab [cited 2019 may 2017]. Available from https://investor.alderbio.com/news-releases/ news-release-details/alder-announces-eptinezumab-significantly-reduces-migraine-riskhttps://www.alderbio.com/pipeline/eptinezumab/Rubio-Beltran E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018;19(1). DOI:10.1186/s10194-018-0893-8Rubio-Beltran E, Correnti E, Deen M, et al. PACAP38 and PAC1 receptor blockade: a new target for headache? J Headache Pain. 2018;19(1). DOI:10.1186/s10194-018-0893-8Moldovan Loomis C, Dutzar B, Ojala E, et al. Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide. Journal of Pharmacology and Experimental Therapeutics. 2019;369(1):26-36. DOI:10.1124/jpet.118.253443Moldovan Loomis C, Dutzar B, Ojala E, et al. Pharmacologic Characterization of ALD1910, a Potent Humanized Monoclonal Antibody against the Pituitary Adenylate Cyclase-Activating Peptide. Journal of Pharmacology and Experimental Therapeutics. 2019;369(1):26-36. DOI:10.1124/jpet.118.253443Alder BioPharmaceuticals, Inc [Internet]. Alder BioPharmaceuticals Reports First Quarter 2019 Financial and Operating Results [cited 2019 May 7]. Available from https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-reports-first-quarter-2019-financialAlder BioPharmaceuticals, Inc [Internet]. Alder BioPharmaceuticals Reports First Quarter 2019 Financial and Operating Results [cited 2019 May 7]. Available from https://investor.alderbio.com/news-releases/news-release-details/alder-biopharmaceuticalsr-reports-first-quarter-2019-financialclinicaltrials.gov [Internet]. Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention [cited 2019 May 7]. [Available from https://clinicaltrials.gov/ct2/show/NCT03238781clinicaltrials.gov [Internet]. Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention [cited 2019 May 7]. [Available from https://clinicaltrials.gov/ct2/show/NCT03238781Gratton S, Cossack M. Answering the Call: A Prospective Look at the Role of Timolol Eye Drops in the Treatment of Acute Migraine. Missouri Medicine. 2018;115(6):520-521.Gratton S, Cossack M. Answering the Call: A Prospective Look at the Role of Timolol Eye Drops in the Treatment of Acute Migraine. Missouri Medicine. 2018;115(6):520-521.clinicaltrials.gov [Internet]. A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03836664clinicaltrials.gov [Internet]. A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03836664Ionis [Internet]. Ionis Innovation: Our antisense-powered pipeline [cited 2019 May 7] // Available from https://www.ionispharma.com/ionis-innovation/pipeline/Ionis [Internet]. Ionis Innovation: Our antisense-powered pipeline [cited 2019 May 7] // Available from https://www.ionispharma.com/ionis-innovation/pipeline/clinicaltrials.gov [Internet]. Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03108469clinicaltrials.gov [Internet]. Efficacy and Safety of IONIS-PKKRx for Preventive Treatment of Chronic Migraine [cited 2019 May 7]. Available from https://clinicaltrials.gov/ct2/show/NCT03108469Tepper S, Dodick D, Schmidt P, Kellerman D. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches. Headache: The Journal of Head and Face Pain. 2019;59(4):509-517. DOI:10.1111/head.13482Tepper S, Dodick D, Schmidt P, Kellerman D. Efficacy of ADAM Zolmitriptan for the Acute Treatment of Difficult-to-Treat Migraine Headaches. Headache: The Journal of Head and Face Pain. 2019;59(4):509-517. DOI:10.1111/head.13482clinicaltrials.gov [Internet]. A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine (ADAM) [cited 2019 May 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT03282227clinicaltrials.gov [Internet]. A Study to Evaluate the Long-Term Safety of M207 in the Acute Treatment of Migraine (ADAM) [cited 2019 May 7]. Available from: https://clinicaltrials.gov/ct2/show/NCT03282227ZosanoPharma [Internet]. Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study [cited 2019 May 7]. Available from http://ir.zosanopharma.com/news-releases/news-release-details/zosano-treats-over-4000-migraines-and-reaches-important-goalZosanoPharma [Internet]. Zosano Treats over 4,000 Migraines and Reaches an Important Goal in M207-ADAM Long-term Safety Study [cited 2019 May 7]. Available from http://ir.zosanopharma.com/news-releases/news-release-details/zosano-treats-over-4000-migraines-and-reaches-important-goal

The authors declare that there are no conflicts of interest present.